Following a full submission under the end of life and orphan equivalent medicine process:
selinexor (Nexpovio®) is accepted for use within NHSScotland.
Indication under review: in combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
In a single-arm, open-label, phase IIb study, selinexor plus dexamethasone resulted in an overall response rate of 25%, in patients with multiple myeloma that was refractory to bortezomib, carfilzomib, lenalidomide, pomalidomide and daratumumab.
This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.
This advice takes account of the views from a Patient and Clinician Engagement (PACE) meeting.
Medicine details
- Medicine name:
- selinexor (Nexpovio)
- SMC ID:
- SMC2673
- Indication:
In combination with dexamethasone for the treatment of multiple myeloma in adult patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, two immunomodulatory agents and an anti-CD38 monoclonal antibody, and who have demonstrated disease progression on the last therapy.
- Pharmaceutical company
- Menarini Stemline
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 07 October 2024